KR20070095900A - 세포 내 글루타티온 및 ａｔｐ의 전달 향상을 통하여저산소증을 치료하기 위한 리보스-시스테인의 용도 - Google Patents

세포 내 글루타티온 및 ａｔｐ의 전달 향상을 통하여저산소증을 치료하기 위한 리보스-시스테인의 용도 Download PDF

Info

Publication number
KR20070095900A
KR20070095900A KR1020077013535A KR20077013535A KR20070095900A KR 20070095900 A KR20070095900 A KR 20070095900A KR 1020077013535 A KR1020077013535 A KR 1020077013535A KR 20077013535 A KR20077013535 A KR 20077013535A KR 20070095900 A KR20070095900 A KR 20070095900A
Authority
KR
South Korea
Prior art keywords
ribcys
hypoxia
mammal
gsh
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077013535A
Other languages
English (en)
Korean (ko)
Inventor
허버트 티. 나가사와
Original Assignee
바이오슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오슈티칼스, 인크. filed Critical 바이오슈티칼스, 인크.
Publication of KR20070095900A publication Critical patent/KR20070095900A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020077013535A 2004-11-17 2005-11-16 세포 내 글루타티온 및 ａｔｐ의 전달 향상을 통하여저산소증을 치료하기 위한 리보스-시스테인의 용도 Ceased KR20070095900A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,933 2004-11-17
US10/990,933 US20060105972A1 (en) 2004-11-17 2004-11-17 Method to enhance delivery of glutathione and ATP levels in cells

Publications (1)

Publication Number Publication Date
KR20070095900A true KR20070095900A (ko) 2007-10-01

Family

ID=35759146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013535A Ceased KR20070095900A (ko) 2004-11-17 2005-11-16 세포 내 글루타티온 및 ａｔｐ의 전달 향상을 통하여저산소증을 치료하기 위한 리보스-시스테인의 용도

Country Status (14)

Country Link
US (4) US20060105972A1 (https=)
EP (1) EP1824481B1 (https=)
JP (1) JP2008520681A (https=)
KR (1) KR20070095900A (https=)
CN (1) CN101060840A (https=)
AU (1) AU2005307885B2 (https=)
BR (1) BRPI0516814A (https=)
CA (1) CA2587616C (https=)
DK (1) DK1824481T3 (https=)
EA (1) EA014076B1 (https=)
ES (1) ES2390228T3 (https=)
MX (1) MX2007005835A (https=)
PL (1) PL1824481T3 (https=)
WO (1) WO2006055597A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
JP4982755B2 (ja) * 2006-06-27 2012-07-25 国立大学法人 長崎大学 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
CN106138071A (zh) * 2008-04-02 2016-11-23 生物能公司 核糖在对于急性心肌梗塞的第一反应中的用途
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
TW201202209A (en) * 2010-01-28 2012-01-16 Max International Llc Methods of preparing thiazolidines
US20110287109A1 (en) * 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products
WO2013016636A1 (en) * 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
EP3297643A4 (en) * 2015-05-22 2019-02-06 The A2 Milk Company Limited BETA-CASEIN-A2 AND ANTIOXIDATIVE CAPACITY
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
JPS63152325A (ja) 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
JP2873089B2 (ja) * 1991-04-15 1999-03-24 帝人株式会社 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US6730336B2 (en) 1998-01-30 2004-05-04 The Procter & Gamble Co. Fortified beverages with improved texture and flavor impact at lower dosage of solids
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US7153503B1 (en) 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
US6534480B2 (en) * 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6881425B2 (en) 2001-08-31 2005-04-19 Council Of Scientific And Industrial Research Custom made herbal health promotive formulation for females/expectant mothers
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US7455857B2 (en) 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
GB0319463D0 (en) 2003-08-20 2003-09-17 Givaudan Sa Compounds
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20060105972A1 (en) 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
BRPI0621321A2 (pt) 2006-02-10 2011-12-06 Mannatech Inc formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
US20100074969A1 (en) 2008-09-19 2010-03-25 Unicity International, Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
TW201201712A (en) 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20110287109A1 (en) 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products

Also Published As

Publication number Publication date
MX2007005835A (es) 2007-10-08
WO2006055597A1 (en) 2006-05-26
JP2008520681A (ja) 2008-06-19
DK1824481T3 (da) 2012-09-24
CA2587616A1 (en) 2006-05-26
AU2005307885B2 (en) 2010-12-23
US9144570B2 (en) 2015-09-29
ES2390228T3 (es) 2012-11-07
EP1824481A1 (en) 2007-08-29
AU2005307885A2 (en) 2006-05-26
EA200701017A1 (ru) 2007-10-26
AU2005307885A1 (en) 2006-05-26
EP1824481B1 (en) 2012-08-29
US8501700B2 (en) 2013-08-06
US20090042822A1 (en) 2009-02-12
US20060105972A1 (en) 2006-05-18
CN101060840A (zh) 2007-10-24
PL1824481T3 (pl) 2012-11-30
BRPI0516814A (pt) 2008-09-23
US20160082029A1 (en) 2016-03-24
US20130317072A1 (en) 2013-11-28
EA014076B1 (ru) 2010-08-30
CA2587616C (en) 2015-03-17

Similar Documents

Publication Publication Date Title
US9144570B2 (en) Method to enhance delivery of glutathione and ATP levels in cells
O'Connell et al. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide
FI97891C (fi) Menetelmä 2'-deoksiguanosiinin asyylijohdannaisten valmistamiseksi
AU703609B2 (en) Protective agent for organ or tissue
EP0549660A1 (en) Enhancement of glutathione levels with glutamine
US20050187271A1 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or its physiologically tolerable salts as a cancer-fighting agent
US4898886A (en) Urea against adenocarcinoma
US11253495B2 (en) Pharmaceutical composition for treating excessive lactate production and acidemia
KR100406848B1 (ko) 프로디지오신의 당뇨병 예방 및 치료용 조성물
ES2271265T3 (es) Utilizacion de mangafodipir en el tratamiento de insuficiencia hepatocelular.
HK1114501A (en) Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells
CN107698639A (zh) 一类吉西他滨磷酸酯的n‑甲酸酯乏氧活化前药及其应用
TW423970B (en) Preventive or therapeutic agent for lung injury caused by active oxygens and free radicals
CN115181099B (zh) 一种醌类化合物及其药学应用
JP2020100601A (ja) 一酸化窒素合成酵素活性化剤
JPS59130213A (ja) 抗腫瘍方法及び組成物
UA139441U (uk) Спосіб корекції неалкогольної жирової хвороби печінки
CN121971416A (en) Application of 1-hydroxy-2-butanone in treating acute liver injury
UA126122U (uk) Спосіб лікування інсулінорезистентності у хворих на цукровий діабет типу 2 із супровідним неалкогольним стеатогепатитом
MD4926C1 (ro) L-enantiomer al hidroxibutandioatului de 2-etil-6-metil-3-hidroxipiridiniu cu activitate biologică înaltă
JP2007016008A (ja) 抗腫瘍剤
Horwitt XI. Pharmacology and Toxicology
Plante Excretion of uric acid in man and the dog.
JPWO1988000182A1 (ja) ｒ‐Ｌ‐グルタミル‐Ｌ‐システインエチルエステル及びそれを有効成分とする医薬
CN101352429A (zh) 硫普罗宁在制备治疗因脑缺血、糖尿病、肥胖继发的肝功能受损的药物中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101115

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20110419

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120930

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120930

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I